Over the years, clinical and experimental studies have established the pivotal role of neurogenic factors in the genesis, progression, and prognosis of hypertension. It is accepted that sympathetic nervous system dominance over vagal influence is largely responsible for hypertension. Such an imbalance is seen strikingly in resistant hypertension. Lifestyle modifications leading to reduced sympathetic tone and increased vagal tone consistently provide control of hypertension and to some extent reversal or delaying of end-organ damage. However, studies with pharmacological and device-based therapies that aimed to modify autonomic tone to regulate neurogenic factors and to achieve desired blood pressure control have not produced encouraging results. The role of beta-blocker drugs has also been questioned. Catheter-based renal denervation strategy has fallen short of expectation. Understanding thoroughly the mechanisms underlying alterations in the neurogenic factors, the result of abnormal neurogenic milieu at the cellular and molecular levels and methods to identify susceptible individuals either by genetic study or by accurate measures of autonomic tone is expected to help tailor anti-hypertensive therapy and thereby improve outcomes.
INTRODUCTION
Extensive research regarding the pathogenesis of hy pertension over last several decades has established that hypertension is the result of highly complex and multifactorial mechanisms. 1 Neurogenic factors have been regarded to exert the maximum influence on not only the pathogenesis of hypertension but also its main tenance, aggravation, and adverse sequelae. 1, 2 Tilting of neurogenic environment toward autonomic sympathetic dominance has the potential to promote hypertension by adversely affecting the vascular reactivity, blood vessel elasticity, blood viscosity, circulating blood volume, and cardiac output. 3 Autoimmunity and inflammation favor ing hypertension can also be modulated by neurogenic factors. 4 Many of the mechanisms involved in genetic and lifestyle predisposition to hypertension are based on neurogenic factors as effectors. The pathophysio logical role of neurogenic factors is discussed and de bated in the guidelines. They are not solely because of the lack of evidence for their role. The lack of evidencebased proofofsignificant benefit in the clinical medicine by the therapies to modulate neurogenic factors contribute dominantly to the controversy. 5, 6 Current strategy of regu lating favorably the neurogenic factors is fraught with adverse hemodynamic, metabolic, and endocrinologic consequences. 5, 7 Further understanding of the neural mechanisms governing blood pressure (BP) regulation will yield possible newer and rational drugs to treat hypertension.
Evidence for Neurogenic Factors in Hypertension
The theory of neurogenic factors regulating BPs received credence as early as in the beginning of 20th century when observations of rise of BP in response to psycho emotional stimuli and control of hypertension by bilateral splanchnicectomy were made. 1,2 The diurnal variation of BP even in normotensive individuals is the result of neurogenic factors exemplified by lower BP level during sleep when there is low sympathetic drive and surge in BP to its overdrive on awakening.
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The microneurographic studies have shown that the number and amplitude of sympathetic bursts are higher not only in individuals with a family history of hypertension but also in those with whitecoat and masked hypertension. 2 Evidence is strong to prove that sympathetic overdrive is not a mere epiphenomenon and it is imperative in the endorgan damage. Higher levels of sympathetic discharg es are seen in patients with left ventricular hypertrophy or dysfunction, renal dysfunction, and other vasculopathies. 3 The histofluorescent and electron microscopic analysis of the sympathetic innervations have revealed that the vessels and the organs in subjects with longstanding hypertension and typically with endorgan damage have a greater density of sympathetic innervations. 2 Excess sympathetic nerve discharge is noted in young, middleaged, and elderly hypertensive individuals, in pregnancyinduced hypertension, and also in hyperten sion associated with metabolic syndromes. In addition to sympathetic hyperactivity, a concomitant diminished vagal influence is often seen in hypertension. 1, 2 Constant sympathetic discharges peripherally lead to downregulation of adrenergic receptors that may partly offset the consequences of sympathetic hyperactivation. However, central sympathetic tonic discharges and concomitant hypovagal milieu perpetuate adverse neurogenic influence. Indeed, sympathetic activation is normally more pronounced in longstanding and complicated stages of hypertension. 1, 2 Recently, the genetic mechanisms predisposing to increased sympathetic tone and hypertension have received attention. 8 A geneencoding melanocortin4
receptor is considered to regulate BP via adrenergic mechanisms. Subjects showing a melanocortin4 receptor deficiency display a reduced adrenergic function coupled with lowBP values. Another geneencoding phosducin is being implicated. Phosducin plays a role in modulating the adrenergic and BP responses to stress and thus in determining stressinduced hypertension. A specific polymorphism of α1Aadrenoreceptor gene is associated with hypertensive patients affected by metabolic syndrome. It is also seen that the putative genetic, environmental, and immunological factors implicated in essential hypertension become effective when neural mechanisms loose equilibrium. 2 The exact mechanisms that trigger altered neurogenic milieu are unclear. However, what is known clearly is that they do not necessarily reside centrally and they may reside in a peripheral organ and they are governed by "feedback" loop.

Neurogenic Axis and the Neurogenic Factors in Blood Pressure Control
The regulatory region of central autonomic nervous system that synthesizes the afferent inputs and sends efferent commands is believed to be situated over a wide area in the midbrain and medulla. 9 It receives continuous information from the pressuresensitive nerve endings (baroreceptors) situated in the carotid sinus and aortic arch, chemoreceptors in the carotid body, pulmonary parenchyma, and also inputs from the limbic, cortical, and midbrain structures, which are sensitive to behavioral changes. Afferent fibers from baroreceptors terminate within the nucleus tractus solitarii (NTS), located in caudal medulla and excite secondorder neurons via a gluta matergic synapse. The secondorder neurons from NTS then reach caudal and rostral ventrolateral medulla (RVLM), which in turn provide tonic excitatory drive to the preganglionic sympathetic neurons in the spinal cord. Stimulation of rostral ventral medulla by gluta mate or electrical stimulation produces rise in BP. Such response can be blocked completely by cervical spinal cord transaction and partially by pharmacological blockade of α and βadrenoceptor blockers. Microin jection of γaminobutyric acid (GABA) into the RVLM produces a marked and dosedependent reduction of arterial pressure.
Vasomotor sympathetic nerve discharge is also influ enced by the paraventricular nucleus of the hypothala mus (PVH) by its connections with lower brainstem and spinal cord. The cells in the anteroventral region of the third ventricle of the hypothalamus (AV3V) are sensitive to plasma concentrations of several hormones related to arterial pressure and body fluid composition. The signals originating from here are transmitted to the PVH. 9 Nitric oxide produced in the NTS and the RVLM is an inhibitory modulator of central sympathetic outflow by regulating glutamate release. Brain angiotensin II enhances sympathetic outflow by blunting the sensitivity of the baroreflex and stimulates secretion of vasopressin via its action at various hypothalamic and medullary areas. These central actions of angiotensin II are medi ated by AT 1 receptors. Peripherally, angiotensin II at the nerve endings increases catecholamine release through AT 1 presynaptic mechanisms and decrease presynaptic reuptake. The sympathetic neural influences on BP con trol are mediated by one or more of the following four efferent limbs: Cardiac postganglionic sympathetic chain, vascular postganglionic sympathetic chain, adrenal med ullary release of catecholamines, and activation of renin angiotensinaldosterone axis through stimulation of renal juxtaglomerular apparatus. The cardiac postganglionic sympathetic chain discharges regulate rhythm, contrac tility. The postganglionic vascular sympathetic discharge result in increased vascular tone that is mediated by enhanced calcium influx through voltagedependent calcium channels. The renal sympathetic nerve activa tion promotes reninangiotensinaldosterone axis. Such activation results in antinatriuresis via reduced renal tubular sodium excretion and increased renovascular resistance.
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Therapeutic Implications
The benefits of BP lowering treatment are well established. The largestever metaanalysis of hypertension treat ment trials, which was published recently, included 123 randomized controlled trials (over 600,000 participants) published between 1996 and 2015. Each 10 mm Hg reduction in systolic BP reduced the relative risk of major cardiovascular events by 20% and allcause mortality by 13%. 10 Lifestyle modification in the form of behavioral changes to minimize mental stress and anxiety, physical exercise, and weight reduction alter neurogenic factors to achieve reduced sympathetic drive and increased parasympathetic drive. 5 Dietary sodium restriction may aggravate the already present sympathetic activation in certain cases. It may be prudent to not to prescribe low salt diet to all hypertension patients.
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Ironically, usefulness of betablocker drugs, which act primarily at sympathetic nervous system in the manage ment of hypertension, has come into question. 6, 7 Experts hesitate to consider betablockers as the first line of antihypertensive drugs. Several trials and metaanalyses have shown that they are inadequate in preventing coro nary events and strokes and also highlighted side effects. Paradoxically, the same experts regard betablockers as first choice in patients at a high risk for coronary disease, postmyocardial infarction (MI), or heart failure. 5 The rel egation of betablockers to inferior position may be result of trial designs, inadequate and nonselective sympathetic blockade, or their combinations.
57
The central sympatholytics such as methyldopa, clo nidine, reserpine, and guanethidine and peripheral alfa blockers also have fallen out of favor due to their side effects and inferior outcomes in antihypertensive drug trials. 5 The drugs recommended to treat hypertension either directly or indirectly alter favorably the influence of neurogenic factors. 5 Calcium channel blockers dimin ish calcium influx into vascular smooth muscle cells by interfering with voltagedependent calcium channels.
5
These channels are activated by adrenoreceptor stimula tion. Angiotensin converter inhibitors and angiotensin receptor inhibitors block reninangiotensinaldosterone axis and thus reduce the deleterious effects of sympa thetic hyperactivity. 5 Successful treatment of hypertension however is diffi cult. The prevalence of resistant hypertension is reported to be ranging from 5 to 20% of cases. 12 It is acknowledged that, for those diagnosed with resistant hypertension, therapeutic options are limited and these patients have a threefold increase in cardiovascular risk compared with those with controlled hypertension, emphasizing the need for alternative therapeutic options beyond pharmacological strategies. Selective disruption of sympathetic nerve supply to achieve BP control was hypothesized after the results of wider surgical resection of thoracic, abdominal, and pelvic sympathetic nerves for resistant hypertension were analyzed.
1,2 Even though sustained BP control was achieved, perioperative mortality was high, and long term deleterious effects including significant dysfunction of organs (bladder, bowel, and genitals) supplied by these nerves were noted. Renal sympathetic nerves, afferent and efferent, which are embodied within the wall of the renal artery and are required for maintenance of hypertension, became an attractive target for selective disruption of sympathetic nerve supply. Percutaneous transcatheter renal artery denervation, first explored in the early 2000s, has become one of the options to treat resistant hypertension. 13 Few trials are underway to determine the optimal ways of achieving denervation. Electrical stimulation of the carotid sinus baroreflex system, or baroreflex activation therapy, may decrease BP in patients with resistant hypertension. Feasibility studies have shown reductions in BP after implantation of a device designed to stimulate the carotid baroreflex system. 14 The technique of deep brain stimulation as a therapy for hypertension was hypothesized when its effect of lowering of BP was noted in patients with neuropathic pain. The reduction in BP was attributed to improved baroreflex sensitivity. The target for stimulation is the ventrolateral periaqueductal gray, which influences the autonomic outflow.
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CONCLUSION
Research has irrefutably established the pivotal role of neurogenic factors in the regulation of BP. Lack of signifi cant clinical benefit by pharmacological and measures to modulate neurogenic factors has highlighted the need to understand neural mechanisms of hypertensions better. In the wake of increasing burden of hypertension and increasing prevalence of resistant hypertension, a fresh look at the more selective betablockers with better anti hypertensive profile is recommended. Novel nonpharma cological therapies to modulate the neurogenic factors in the management of hypertension hold promise.
